<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer

Standard first-line chemotherapy in small cell lung cancer (SCLC) is based on the platinum plus etoposide combination. Despite a high objective response rate, responses are not durable and chemotherapy-induced toxicity may compromise treatment. Genetic variants in genes involved in the DNA-repair pa...

Descrizione completa

Dettagli Bibliografici
Autori principali: Andrés Barba, Laura López-Vilaró, Malena Ferre, Margarita Majem, Sergio Martinez-Recio, Olga Bell, María J. Arranz, Juliana Salazar, Ivana Sullivan
Natura: Articolo
Lingua:English
Pubblicazione: MDPI AG 2024-08-01
Serie:Pharmaceutics
Soggetti:
<i>ERCC1</i>
<i>ERCC2</i>
platinum-based chemotherapy
small cell lung cancer
pharmacogenomics
Accesso online:https://www.mdpi.com/1999-4923/16/9/1121

Accesso online

https://www.mdpi.com/1999-4923/16/9/1121

Documenti analoghi